FDA approves Tygacil for drug-resistant infections

The Food and Drug Administration said this morning it is approving Tygacil, a member of a new class of antibiotics developed to fight drug-resistant infections. Developed by pharma giant Wyeth, the intravenously administered drug has been shown to be useful against the kind of dangerous infections which have become an increasing concern at hospitals in the US and elsewhere in recent years. In particular, research has shown the drug to be useful for treating the "Superbug" MRSA. Tygacil is derived from the old Tetrocycline class.

- see this story from the San Jose Mercury News

Post a comment